Should angiotensin II receptor blockers and statins be combined?

Circulation

Volumn 110, Issue 8, 2004, Pages 1013-1020

  Nickenig, Georg ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Cardiovascular diseases; Heart failure; Receptors, angiotensin; Statins; Syndrome X

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; RENIN; SIMVASTATIN; THIAZIDE DIURETIC AGENT; VALSARTAN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; METABOLIC DISORDER; MORBIDITY; MORTALITY; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; SIDE EFFECT; STROKE; SURVIVAL; TREATMENT INDICATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; CORONARY ARTERIOSCLEROSIS; DIABETES COMPLICATIONS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; HEART FAILURE, CONGESTIVE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERTENSION; METABOLIC SYNDROME X; OXIDATIVE STRESS; RABBITS; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RENIN-ANGIOTENSIN SYSTEM; VASOCONSTRICTION;

EID: 4344612855     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000139857.85424.45     Document Type: Review

References (80)

1. Kannel WB. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens. 2000;1:3S-10S.
2. Sander GE, Giles TD. Hypertension and lipids: lipid factors in the hypertension syndrome. Curr Hypenens Rep. 2002;4:458-463.
3. Ginsberg HN, Stalenhoef AF. The metabolic syndrome: targeting dyslipidaemia to reduce coronary risk. J Cardiovasc Risk. 2003;10:121-128.
4. 1 receptor regulation. Circulation. 2002;105:530-536.
5. 1-type angiotensin receptor in oxidative stress and atherogenesis, part I: oxidative stress and atherogenesis. Circulation. 2002;105:393-396.
6. Unger T. Blood pressure lowering and renin-angiotensin system blockade. J Hypertens. 2003;21(suppl 6):S3-S7.
7. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-1675.
8. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
9. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
10. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
11. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362:759-766.
12. Pfeffer MA. McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engt J Med. 2003;349:1893-1906.
13. Schupp M, Janke J, Clasen R, et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor activity. Circulation. 2004;109:2054-2057.
14. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR-modulating activity. Hypertension. 2004;43:1-10.
15. Fuentes R, Uusitalo T, Puska P, et al. Blood cholesterol level and prevalence of hypercholesterolaemia in developing countries: a review of population-based studies carried out from 1979 to 2002. J Cardiovasc Risk. 2003;10:411-419.
16. Sowers JR. Effects of statins on the vasculature: implications for aggressive lipid management in the cardiovascular metabolic syndrome. Am J Cardiol 2003;91M4B-22B.
17. Werner N, Nickenig G, Laufs U. Pleiotropic effects of HMG-CoA reductase inhibitors. Basic Res Cardiol. 2002;97:105-116.
18. Wassmann S, Nickenig G. Interrelationship of free oxygen radicals and endothelial dysfunction: modulation by statins. Endothelium. 2003;10:23-33.
19. Dzau VJ, Bernstein K, Celermajer D, et al. The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. Am J Cardiol. 2001;88:1L-20L.
20. Lavy A, Brook GJ, Dankner G, et al. Enhanced in vitro oxidation of plasma lipoproteins derived from hypercholesterolemic patients. Metabolism. 1991;40:794-799.
21. Harrison DG. Endothelial function and oxidant stress. Clin Cardiol. 1997;20:II-7.
22. Prasad A, Tupas-Habib T, Schenke WH, et al. Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. Circulation. 2000;101:2349-2354.
23. 1 receptor blockade on endothelial function in essential hypertension. Am J Hypertens. 2003;16:123-128.
24. Wassmann S, Hilgers S, Laufs U, et al. Angiotensin II type receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction. Arteriosder Thromb Vasc Biol. 2002;22:1208-1212.
25. Castelli WP, Garrison RJ, Wilson PW, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA. 1986;256:2835-2838.
26. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-126.
27. 1-receptor expression. Am J Physiol. 1997;272:H2701-H2707.
28. 1 receptor function and density in hypercholesterolemic men. Circulation. 1999;100:2131-2134.
29. Warnholtz A, Nickenig G, Schulz E, et al. Increased NADH-oxidase-mediated Superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation. 1999;99:2027-2033.
30. Nickenig G, Sachinidis A, Michaelsen F, et al. Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation. 1997;95:473-478.
31. Lusis AJ. Atherosclerosis. Nature. 2000;407:233-241.
32. Aviram M. Interaction of oxidized low density lipoprotein with macrophages in atherosclerosis, and the antiatherogenicity of antioxidants. Eur J Clin Chem Clin Biochem. 1996;34:599-608.
33. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-1307.
34. Oi S, Haneda T, Osaki J, et al. Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells. Eur J Pharmacol. 1999;376:139-148.
35. Park JK, Muller DN, Mervaala EM, et al. Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects. Kidney Int. 2000;58:1420-1430.
36. 1 receptor expression and Racl GTPase. Mol Pharmacol. 2001;59:646-654.
37. Wassmann S, Laufs U, Baumer AT, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension. 2001;37:1450-1457.
38. Muller DN, Dechend R, Mervaala EM, et al. NF-κB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension. 2000;35:193-201.
39. Wassmann S, Stumpf M, Strehlow K, et al. Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circ Res. 2004;94:534-541.
40. Wu L, Iwai M, Nakagami H, et al. Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury. Circulation. 2001;104:2716-2721.
41. Urata H, Kinoshita A, Misono KS, et al. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem. 1990;265:22348-22357.
42. Burnier M, Brunner HR. Angiotensin II receptor antagonists in hypertension. Kidney Int Suppl. 1998;68:S107-S111.
43. Elliott WJ. Therapeutic trials comparing angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. Curr Hypertens Rep. 2000;2:402-411.
44. Kjeldsen SE, Dahlof B, Devereux RB, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA. 2002;288:1491-1498.
45. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:1004-1010.
46. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 2002;106:672-678.
47. Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther. 1998;20:671-681.
48. Istvan E. Statin inhibition of HMG-CoA reductase: a 3-dimensional view. Atherosder Suppl. 2003;4:3-8.
49. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
50. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001-1009.
51. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339:1349-1357.
52. Black DM. A general assessment of the safety of HMG CoA reductase inhibitors (statins). Curr Atherosder Rep. 2002;4:34-41.
53. Downs JR, Clearfield M. Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-1622.
54. Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol. 2002;40:567-572.
55. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711-1718.
56. MRC/BHF Heart Protection Study (HPS) of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
57. Brewer HB Jr. New features of the National Cholesterol Education Program Adult Treatment Panel III lipid-lowering guidelines. Clin Cardiol. 2003;26:III-19-III-24.
58. Horiuchi M, Cui TX, Li Z, et al. Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation. Circulation. 2003;107:106-112.
59. Hussein O, Shneider J, Rosenblat M, et al. Valsartan therapy has additive anti-oxidative effect to that of fluvastatin therapy against low-density lipoprotein oxidation: studies in hypercholesterolemic and hypertensive patients. J Cardiovasc Pharmacol. 2002;40:28-34.
60. Nazzaro P, Manzari M, Merlo M, et al. Distinct and combined vascular effects of ACE blockade and HMG-CoA reductase inhibition in hypertensive subjects. Hypertension. 1999;33:719-725.
61. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
62. Dickstein K, Kjekshus J, OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial: Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002;360:752-760.
63. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-1158.
64. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326:1419.
65. Castelli WP. Epidemiology of coronary heart disease: the Framingham study. Am J Med. 1984;76:4-12.
66. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173-194.
67. Keller KB, Lemberg L. Obesity and the metabolic syndrome. Am J Crit Care. 2003;12:167-170.
68. Ginsberg HN. Treatment for patients with the metabolic syndrome. Am J Cardiol 2003;91:29E-39E.
69. Handler J. Opportunity for JNC VII. J Clin Hypenens (Greenwich). 2003;5:15-16.
70. Zimmet P. Globalization, coca-colonization and the chronic disease epidemic: can the Doomsday scenario be averted? J Intern Med. 2000;247:301-310.
71. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782-787.
72. 1 receptor gene expression by posttranscriptional mechanisms. Circulation. 1998;98:2453-2460.
73. Gorelick PB, Sacco RL, Smith DB, et al. Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. JAMA. 1999;281:1112-1120.
74. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease, part 2: short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827-838.
75. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack (PROGRESS). Lancet. 2001;358:1033-1041.
76. Lithell H, Hansson L, Skoog I, SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21:875-886.
77. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326:1423.
78. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial: the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582-1587.
79. Laufs U, Kilter H, Konkol C, et al. Impact of HMG CoA reductase inhibition on small GTPases in the heart. Cardiovasc Res. 2002;53:911-920.
80. Maack C, Kartes T, Kilter H, et al. Oxygen free-radical release in human failing myocardium is associated with increased activity of racl-GTPase and represents a target for statin treatment. Circulation. 2003;108:1567-1574.